Correlation Between Inozyme Pharma and Corvus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Corvus Pharmaceuticals, you can compare the effects of market volatilities on Inozyme Pharma and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Corvus Pharmaceuticals.

Diversification Opportunities for Inozyme Pharma and Corvus Pharmaceuticals

0.62

Correlation Coefficient

Inozyme Pharma  Corvus Pharmaceuticals

Poor diversification

The 3 months correlation between Inozyme and Corvus is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Corvus Pharmaceuticals

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Corvus Pharmaceuticals. In addition to that, Inozyme Pharma is 1.45 times more volatile than Corvus Pharmaceuticals. It trades about -0.25 of its total potential returns per unit of risk. Corvus Pharmaceuticals is currently generating about -0.15 per unit of volatility. If you would invest  525.00  in Corvus Pharmaceuticals on December 29, 2024 and sell it today you would lose (187.00) from holding Corvus Pharmaceuticals or give up 35.62% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Corvus Pharmaceuticals

Inozyme Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Corvus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Corvus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Inozyme Pharma and Corvus Pharmaceuticals

The main advantage of trading using opposite Inozyme Pharma and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.

The idea behind Inozyme Pharma and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.